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Background. We sought to characterize the epidemiology of HIV and S. stercoralis coinfection in an urban HIV cohort, and to investigate the effect of S. stercoralis infection on HIV virologic control and immune recovery.
Methods. We reviewed the medical records of all HIV-infected patients diagnosed with strongyloidiasis who received care at Thomas Street Health Center (Houston, TX) between 2000 and 2015. For each case we included up to two matched HIV-infected patients without strongyloidiasis (controls). Matching was based on age, sex, ethnicity, baseline CD4 percentage, and HIV viral load at the time of strongyloidiasis diagnosis in the case patient. We recorded patient demographics, comorbidities, CD4 count and percentage, HIV viral load, and absolute eosinophilia count (AEC) at the time of HIV diagnosis, strongyloidiasis diagnosis, and six and twelve months after ivermectin treatment.
Results. We identified 15 cases of HIV and S.stercoralis coinfection; 13 had at least one available matched control. The mean age of coinfected patients was 45; all were Hispanic, 84.6% were male, and the mean CD4 nadir was 146 cells/ul. At the time of strongyloidiasis diagnosis, the mean CD4 count was 460 cells/ul, HIV RNA viral load 2.07 logs/ml, and AEC was 1,360 cells/μL. At 6 and 12 months after treatment, CD4 counts were 514 and 464 cells/μL, HIV RNA viral loads 1.78 and 2.31 log/mL, and AECs 319 and 362 cells/μL, respectively. Although CD4 counts increased 6 months after treatment, they returned to baseline levels at 12 months; neither change achieved statistical significance. The reduction in AECs after ivermectin treatment was statistically significant (P < 0.001). Matched controls without S.stercoralis had lower AECs at baseline, 6 months, and 12 months; otherwise, there were no differences between cases and controls.
Conclusion. Strongyloidiasis treatment in HIV-infected patients led to normalization of the AEC at 6 months in most cases, but AECs remained higher than in control patients. Persistently elevated AECs may suggest treatment failure or reinfection. Our study was unable to identify any effect of S. stercoralis infection or treatment on HIV virologic suppression or immunologic recovery; larger studies are warranted to investigate the effect of strongyloidiasis on HIV disease.
Disclosures. All authors: No reported disclosures. Background. Infections due to Varicella-zoster virus (VZV) are common in HIV infected patients (HIVP), yet antibody levels to VZV are not routinely measured. To better understand host-VZV dynamics in HIVP plus assess the clinical utility of a commercial assay, IgG levels were measured and correlated with CD4 count, viral load (VL), history (HX) of Herpes zoster (HZ) and demographics.
Varicella zoster Virus IgG Antibody Levels in HIV Infected
Methods. Specimens were processed using a semi-quantitative assay. Results reported as an index: <135 consistent with "absence of immunity, " 135-165 "equivocal", and >165 reflected "immunity. " Cut-off point reported as >4000. Statistical computations were performed in the R computing package (R Core Team 2017). Proportions compared using the exact chi-squared test. Highly skewed variables compared using the Mann-Whitney-Wilcoxon test, and censored variables compared via a generalization of MWW (log-rank).
Results. During 22 months, 426 HIVP enrolled, 284 (66%) males and 142 females; mean age was 44 and 51, respectively. Mean IgG index for all HIVP = 1,886, males = 1,971, females = 1,720 (P = 0.06). However, difference in median IgG was significant (1,730 vs. 1,477; P < 0.0001). Hx of HZ was elicited in 113 (27%), no gender difference (27% vs. 25%, P = 0.55). Frequency of IgG > 4,000 was not significant. HIVP subdivided into 3 age groups for further comparisons. Age≤ = 30: 79 HIVP, 87% of which were males, only 9 (11%) had Hx of HZ, lowest mean IgG = 1,686 and least HIV control. VL< 50 c/mL in 44%. Age 31 to 59: 274 HIVP with mean age of 47, mean IgG = 1,908, and 72% with VL < 50. A Hx of HZ in 86 (31%). Age ≥ 60: 73 HIVP with mean age of 65, mean IgG = 2006. Eighteen had Hx of HZ. Compared with second group, oldest group had better HIV control with VL < 50 in 79% (P = 0.039) yet mean IgG was similar (P = 0.33). Through a logistic regression analysis, the probability of HZ steadily increased as a function of age until about 55. IgG indexes >4,000 were also noted in 58 asymptomatic HIVP.
Conclusion. Intermittent, asymptomatic VZV reactivation occurs in HIVP regardless of prior HZ. IgG < 135 predicted negative Hx of HZ. Pre-existing IgG may not protect against VZV reactivation.
Disclosures. All authors: No reported disclosures. 1 Internal Medicine, U.S. Naval Hospital Guam, Tamuning, AP, Guam, Background. Herpes Zoster (HZ) incidence has decreased over 40% in the United States but remains elevated in persons living with HIV (PLWH). HZ vaccine is not routinely recommended for PLWH and provider-prescribing patterns vary greatly. Updated incidence information in this population is needed to guide vaccine strategies. Using data from the US military HIV Natural History Study (NHS), we evaluated the incidence and risk factors for HZ in the modern ART era.
Incidence of Herpes Zoster in a Large Cohort of Persons Living with HIV
Methods. NHS subjects undergo bi-annual visits with laboratory testing, examinations, and records reviewed for clinical diagnosis, including HZ. Analysis was restricted to subjects contributing to follow-up after 2001. Risk factors for HZ (demographic and HIV-specific) were assessed with a multivariate Cox proportional hazards model.
Results. Of the 2954 subjects meeting inclusion criteria, 237 (8%) were diagnosed with HZ. At HZ diagnosis, the median age, CD4 count, and viral load were 38.6 years 45.8], 638] and 1900 copies/mL [IQR-50, 19580] respectively. The incidence of HZ was highest prior to 1996 at 3.24 cases/100 person-years (PY) of follow-up (2.96-3.54) and declined significantly over time with 1.9 (1.6-2.3), 1.4 (1.2-1.8), 1.4 (1.1-1.7), and 0.9 (0.7-1.2) cases/100 PY recorded in 1996-2000, 2001-2005, 2006-2010, and 2011-2016, respectively . In the multivariate model, longer time from HIV diagnosis to ART initiation was associated with HZ. ART use, higher CD4 count, recent year of HIV diagnosis, and older age were protective (Table 1) .
Conclusion. HZ remains a common diagnosis in the ART era. NHS subjects with HZ were in the fourth and fifth decades of their life and had preserved CD4 counts highlighting the need for HZ vaccine safety and efficacy studies to help guide provider practice. Delays in ART initiation were associated with HZ emphasizing the need for compliance with current ART guidelines. 
